Adarza BioSystems Raises $25 Million in Series D Funding to Launch Platform for Research and Drug Development
Biotech company Adarza BioSystems announced today that it has raised $25 million in a Series D round co-led by 3×5 Partners, based in Portland, Ore., and St. Louis-based Lightchain Capital, LLC, the family office of Scottrade founder Rodger Riney.
Adarza plans to use the funds to support full commercialization of ZIVA, its automated biological testing platform for academic and clinical research. Scheduled for commercial launch in June, the ZIVA platform will allow researchers to quickly identify inflammation, cardiovascular, and oncology protein biomarkers for disease profiling and drug development.